Preventive Cardiology · Physician Briefing

The Convergence Era: CKM Syndrome, Fat Radiomics, and Wearables Reshape Cardiovascular Prevention

A new multisociety guideline, an AI-derived fat signature, and opportunistic imaging are quietly converging into a single question for every clinic visit: how early can risk be seen before disease is felt.

Preventive & Metabolic Cardiology Cardiac Imaging Digital Health Physician-Investor Briefing

01 · A Syndrome Gets a Name and a Playbook

Cardiovascular, kidney, and metabolic disease have always traveled together in the same patients.

The first comprehensive CKM syndrome guideline from the AHA and ACC, developed with the American Diabetes Association and American Society of Nephrology, formally retires the old obesity-only framework.

The guideline frames cardiovascular-kidney-metabolic (CKM) syndrome as a single interconnected condition rather than three separate referrals.

A five-tier staging system anchors the document, running from stage 0 (no risk factors) to stage 4 (established cardiovascular disease).

Stage 3 is the pivotal inflection point, capturing subclinical disease or a predicted ten-year risk of 20% or higher by the PREVENT risk equations.

Roughly 90 to 95 percent of American adults now fall somewhere on this stage 1-to-4 continuum, according to the guideline writers.

That statistic alone reframes CKM syndrome as a population-level default rather than a niche diagnosis.

The document gives a class 1 recommendation to interdisciplinary, team-based care anchored by a designated CKM coordinator for patients in stages 2 through 4.

Pharmacologic strategy leans on three overlapping tools: GLP-1 receptor agonists, SGLT2 inhibitors, and the nonsteroidal mineralocorticoid receptor antagonist finerenone, marketed as Kerendia by Bayer AG.

An accompanying editorial notes that obesity, diabetes, kidney disease, heart failure, and atherosclerotic disease are manifestations of one interconnected pathophysiology rather than isolated diagnoses.

Figure 1. The CKM staging framework positions stage 3 — subclinical disease — as the highest-value window for imaging-based detection.

02 · Fat as a Signal, Not Just a Risk Factor

Long before a guideline can stage a patient, imaging has to find the signal.

A large multicenter study applied automated radiomic phenotyping of epicardial adipose tissue to routine coronary CT angiography scans from more than 72,000 adults without known heart failure.

Epicardial fat is not inert padding around the heart; it is a metabolically active depot that both senses and modulates myocardial biology through paracrine signaling.

Investigators extracted over 1,600 volumetric, shape, and texture features from this fat depot using a fully automated pipeline.

A survival autoencoder model condensed these features into a single fat radiomic profile for heart failure, developed in one cohort and externally validated in a second, geographically distinct cohort.

The signature predicted incident heart failure independent of age, sex, coronary artery disease severity, and epicardial fat volume alone.

Because the underlying scan is already a routine coronary CT, the technique requires no additional radiation, contrast, or patient time.

This positions opportunistic, AI-derived fat analysis as a plausible bridge between a scan ordered for chest pain and a heart failure prevention conversation that would otherwise wait for symptoms.

03 · Coronary Calcium Finds Patients Who Never Asked to Be Scanned

A parallel body of work is chasing the same goal through a more familiar test: the coronary artery calcium (CAC) score.

AI-driven CAC detection on noncardiac CT scans extends calcium scoring to studies never intended for cardiovascular purposes, including lung cancer screening CTs.

This matters because roughly nine million American adults undergo lung cancer screening CT each year, almost none of which are read for cardiac risk.

Traditional ECG-gated CAC scans remain gold standard, but access is uneven and the test is not reliably covered by insurance.

That access gap has been shown to track with socioeconomic and health care disparities, meaning the patients least likely to get a dedicated CAC scan are often those who would benefit most from knowing their number.

Convolutional neural network and U-Net-based models can now extract calcium scores from these already-acquired scans with accuracy approaching dedicated gated studies.

For a physician-investor audience, this is the quiet argument for AI-enabled radiology software as a category, not a single-company bet.

04 · Wearables Move From Rhythm to Ischemia

The third convergence point is on the patient's wrist rather than in the scanner.

Consumer smartwatch electrocardiograms have historically excelled at one thing: flagging atrial fibrillation.

Newer work is testing whether the same hardware, paired with AI-enhanced multi-lead reconstruction, can flag acute coronary syndrome rather than just arrhythmia.

One study applied an AI algorithm trained on standard twelve-lead ECGs to a nine-lead configuration derived from sequential single-lead smartwatch recordings.

Early results suggest meaningful sensitivity and specificity for ischemic change detection, though the authors are careful to frame this as preliminary rather than clinic-ready.

The clinical logic is straightforward: a shortage of specialists to interpret conventional ECGs is a bottleneck that automated interpretation could partially relieve, particularly where access to a standard ECG machine is limited.

None of this replaces a 12-lead ECG or serial troponins in a patient with chest pain, and current guidance still centers on that standard pathway.

What it does offer is a plausible first alert in settings where that pathway is hours away.

Figure 2. Cardiac imaging, opportunistic AI-read calcium scoring, and wearable ECG triage are separate technologies converging on the same clinical target: subclinical disease before it declares itself.

Case Vignette

A 54-year-old warehouse manager with a body mass index of 33, borderline glucose intolerance, and treated hypertension undergoes a low-dose chest CT for lung cancer screening after a 30-pack-year smoking history.

The radiology report is negative for malignancy and, under an AI-assisted opportunistic screening protocol, flags a coronary artery calcium score in the moderate range.

Applying the CKM staging framework, this patient moves from stage 2 to stage 3 on the strength of that single incidental finding.

The case illustrates why opportunistic AI-read CAC, fat radiomics, and structured CKM staging are not competing tools but complementary checkpoints for the same category of patient: metabolically at-risk, asymptomatic, and easy to miss without a systematic prompt.

05 · Where the Capital Is Flowing

For physicians who also track the investable side of prevention, three categories are worth watching: metabolic pharmacotherapy, nonsteroidal MRA therapy, and AI-enabled cardiac imaging software.

Metabolic pharmacotherapy is dominated by two companies whose GLP-1 franchises are now explicitly named in guideline-level management pathways.

Table 1. Selected publicly traded companies relevant to CKM-era prevention

Company	Ticker	Relevant Product(s)	Analyst Consensus
Bayer AG	BAYRY (OTC ADR)	Finerenone (Kerendia) — nonsteroidal MRA for CKD and HF	Buy consensus; average 12-month target near $14
Novo Nordisk A/S	NVO (NYSE ADR)	Semaglutide (Ozempic, Wegovy) — GLP-1 receptor agonist	Buy consensus; average 12-month target near $48
Eli Lilly and Company	LLY (NYSE)	Tirzepatide (Mounjaro, Zepbound) — dual GIP/GLP-1 agonist	Buy/Strong Buy consensus; average 12-month target above $1,200
Cleerly, Inc.	No live ticker — privately held, pre-IPO	AI-based coronary CT plaque and calcium analysis software	Not applicable; private financing rounds only

The pricing gap in the CKM toolkit is stark and worth naming plainly for patient counseling: a 30-tablet supply of 10 mg Kerendia retails near $890 to $908 without insurance, discounted to roughly $640 to $695 with a GoodRx coupon.

No generic finerenone exists yet, with patent protection expected at minimum into 2029.

Bayer's manufacturer copay program can reduce eligible commercially insured patients' out-of-pocket cost to as little as zero dollars per month, capped at $3,000 in annual savings.

Table 2. Three prevention technologies at a glance

Technology	Signal Detected	Added Test Burden	Maturity
Epicardial fat radiomics on CCTA	Future heart failure risk	None — reuses existing scan	Externally validated, not yet commercial
AI-read opportunistic CAC	Subclinical atherosclerosis	None — reuses noncardiac chest CT	Multiple validated algorithms; early clinical rollout
Smartwatch AI-ECG for ACS	Acute ischemic change	Minimal — patient-owned device	Early-stage, preliminary accuracy data only

Bottom Line

The 2026 CKM guideline gives clinicians a shared staging language for a condition that already affects nearly all American adults in some degree.

Epicardial fat radiomics and AI-read opportunistic calcium scoring both extract new prognostic value from scans patients are already getting for other reasons.

Wearable AI-ECG for ischemia detection remains promising but preliminary, and should not yet substitute for standard troponin-and-ECG pathways.

Across all three, the unifying opportunity is the same: catching stage 3 disease before it becomes stage 4.

Physician education disclaimer: This article is intended for healthcare professional education and does not constitute clinical practice guidance for any individual patient; treatment decisions should follow current guideline recommendations and individualized clinical judgment.

Financial disclaimer: Stock tickers, analyst consensus ratings, and pricing figures are provided for general informational and educational purposes only, reflect data available at the time of writing, and do not constitute investment advice; consult a licensed financial advisor before making investment decisions.

References

1. American Heart Association / American College of Cardiology. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome — coverage via TCTMD.
2. American Heart Association Professional Heart Daily. Guideline summary and staging framework for CKM syndrome.
3. Early prediction of heart failure from routine cardiac CT using radiomic phenotyping of epicardial fat — PubMed abstract.
4. Artificial intelligence-driven advances in coronary calcium scoring: expanding preventive cardiology — PubMed Central.
5. Smartwatch ECG and artificial intelligence in detecting acute coronary syndrome compared to traditional 12-lead ECG — PubMed Central.
6. GoodRx. Kerendia (finerenone) pricing and patient assistance information.
7. StockAnalysis.com. Bayer Aktiengesellschaft (BAYRY), Novo Nordisk A/S (NVO), and Eli Lilly and Company (LLY) stock overviews and analyst forecasts.